Research Peptide Procurement: Lot Documentation and Supplier Review
In documentary terms, procuring a research peptide means assembling the records that tie one physical lot to its test results. This page sets out which documents to request for a lot, how a certificate of analysis is matched to the label on the material received, what a certificate does and does not establish, where PepGenex processing takes place, and how PepGenex documentation is requested.
Last reviewed 2026-09-24
What documents should be requested for a research peptide lot?
The core record is the lot's certificate of analysis. ICH Q7 section 11.4 describes what one should carry, and those items are the natural request list:[1]
- The certificate issued for that specific lot, naming the material, its batch number and its date of release.[1]
- For every test on it, the acceptance limit the result was judged against as well as the numerical result itself.[1],[2]
- The identity of the laboratory that carried out the analysis, with an address and telephone number.[1]
- Any expiry or retest date that applies, which ICH Q7 expects on both the label and the certificate.[1]
How is a certificate of analysis matched to the shipped label?
Two identifiers do the matching. ICH Q7 states that a container label should give the name or identifying code and the batch number, so each can be read from the label and compared character by character with the certificate.[1]
If either identifier differs, the certificate is describing a different quantity of material. ICH Q7 regards a batch as uniform only within specified limits, which is why results are not carried from one batch to the next.[1]
What does a certificate of analysis establish, and what does it not?
It establishes the values a laboratory obtained, by the methods it names, on samples from the batch the certificate identifies. ICH Q6B separates identity, purity and impurities, potency and quantity into distinct specification items, so a certificate speaks only to the items it actually reports.[1],[2]
It does not establish where the material was made: none of the specification tests in ICH Q6B measures place of manufacture. Nor does it cover other lots, tests that were not run, or the regulatory status of the material.[2]
Where does processing of PepGenex research materials occur?
PepGenex first-party information. Source: written confirmation from the processing laboratory, dated 2026-09-24.
PepGenex sources the active ingredient from synthesis outside the United States. The stages that follow, and the locations where each one is performed, are listed with their source on the U.S. processing and testing page.
Performing later stages at a U.S. location does not make the finished material of U.S. origin: under 16 CFR 323.2 an unqualified origin claim also depends on where the ingredients were made and sourced.[3]
How is documentation for a PepGenex lot requested?
PepGenex first-party information.
PepGenex research materials undergo independent third-party analytical testing. COA available on request.
Documentation questions can also go through the PepGenex contact page. Institutions with a wholesale account can raise them through the wholesale portal.
What does research use only mean for these materials?
PepGenex supplies these materials for laboratory research only. They are not for human or veterinary use and not for human consumption, and nothing in their documentation is a statement of suitability for any other use.
Where can researchers access PepGenex research materials?
Limitations
The request list above is drawn from what ICH Q7 describes for a certificate; it is not a statement that any supplier's documents, including PepGenex's, meet that guidance.[1]
The processing locations and documentation practices above are first-party information from PepGenex and have not been independently audited.
This page describes what the cited documents say. It is not a statement that any PepGenex material, or any other supplier's material, has been manufactured, tested or released under any of them.
References
- ICH Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients. U.S. FDA guidance for industry, September 2016. FDA docket FDA-1995-D-0288
- ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. U.S. FDA guidance for industry, August 1999. FDA docket FDA-1998-D-0003
- 16 CFR Part 323, Federal Trade Commission rule on U.S.-origin labeling, sections 323.1(a) and 323.2 (current edition). 16 CFR 323.1 · 16 CFR 323.2